Save 10%Multi-pathway matrix & inflammatory-signalling research
KLOW Complete Stack
The four-peptide KLOW blend, with single-compound KPV and GHK-Cu controls.
- 2× KLOW 80mg
- KPV 10mg
- GHK-Cu 50mg

Studio render of the Vial AU vial. Lot details for each size are in the certificates below.
$159.00$1.99/mg
● In stock · same-day dispatch
For in-vitro laboratory research only. Not for human or veterinary use. A research purchasing declaration is required at checkout.
KLOW from Vial AU is a research blend supplied in Australia (80mg) from Sydney, NSW, for in-vitro laboratory research only. It is not for human or veterinary use. 7 certificates of analysis are published in full, each naming its lot, laboratory and test date. The highest published result is 99.45% purity (HPLC, lot APL-KLOW80-2610-05, supplier lab, tested 23 Oct 2026).
KLOW is a four-peptide research blend combining GHK-Cu, BPC-157, TB-500, and KPV in a single lyophilised vial. Each component acts on a distinct pathway. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is studied for copper-dependent enzyme activity, extracellular-matrix remodelling, and broad gene-expression modulation.
| Lot | Lab | Test | Result | Tested | Link |
|---|---|---|---|---|---|
| APL-KLOW80-2610-05 | Supplier lab | purity | 99.45% | 23 Oct 2026 | View KLOW lot APL-KLOW80-2610-05 |
| APL-KLOW80-2609-04 | Supplier lab | purity | 99.38% | 19 Sept 2026 | View KLOW lot APL-KLOW80-2609-04 |
| APL-KLOW80-2608-03 | Supplier lab | purity | 99.31% | 17 Aug 2026 | View KLOW lot APL-KLOW80-2608-03 |
| APL-KLOW80-2607-02 | Supplier lab | purity | 98.94% | 17 July 2026 | View KLOW lot APL-KLOW80-2607-02 |
| APL-KLOW80-2606-01 | Supplier lab | purity | 99.18% | 17 June 2026 | View KLOW lot APL-KLOW80-2606-01 |
| — | Ozcanium Analytics | purity | 99.4% | — | View KLOW purity report |
| — | Janoshik | purity | — | — | View KLOW purity report |
Yes. Vial AU supplies KLOW (80mg) Australia-wide from Sydney, NSW as a research blend for in-vitro laboratory research only. It is not a medicine or an approved therapeutic good, it is not for human or veterinary use, and every order requires a research purchasing declaration.
The highest published result is 99.45% purity (HPLC, lot APL-KLOW80-2610-05, supplier lab, tested 23 Oct 2026). Purity is reported per lot: a size shows a purity figure only when a certificate exists for the exact lot in stock, otherwise it reads "Batch COA pending".
Yes. 2 independent third-party reports are published for KLOW, from Ozcanium Analytics and Janoshik. Supplier batch reports are labelled "Supplier lab", so independent and in-house results are never confused.
7 KLOW certificates are published in full, not sent on request. Each names the lot, the laboratory, the method and the test date. Match the lot code on your vial label to the certificate before relying on a result.
Orders paid by 14:00 AEST/AEDT on a business day are dispatched the same day from Sydney with Australia Post tracking, including to Sydney, Melbourne, Brisbane, Perth, Adelaide, Hobart, Canberra and Darwin. Delivery usually takes 1–3 business days after dispatch; regional and remote addresses can take longer.
Keep the sealed vial dry, protected from light and frozen (around −20 °C) for long-term holding, and let it reach room temperature before opening to limit condensation. Solutions are far less stable than the lyophilised powder, so prepare them close to the experiment.
Supplied for laboratory use.Practice notes: storing lyophilised peptides, choosing a reconstitution solvent and peptide stability in solution. Use the concentration calculator for stock solutions in mg/mL and µM.
Ready-made sets that pair KLOW with the compounds it is most often studied alongside, at a bundle price.
Save 10%Multi-pathway matrix & inflammatory-signalling research
The four-peptide KLOW blend, with single-compound KPV and GHK-Cu controls.



